Connect with us

Business

New THC-CBD Pill for MS and Huntington’s Disease May Be First to Benefit from Biden’s New Marijuana Research Bill

Published

on

MMJ’s cannabis pill for multiple sclerosis and Huntington’s Disease may be up next!

The MMJ trifecta of firms, in partnership with a specialized pharmaceutical soft gelatin production firm, has completed production of its CBD, THC capsule medicine based on compounds in the cannabis plant. The company will conduct clinical trials on its unique pharmaceutical to demonstrate its safety, efficacy, and treatment for individuals with Huntington’s disease (HD) and multiple sclerosis (MS).

Once FDA-approved for usage in clinical trials, MMJ will be the only firm offering a CBD and THC pill that will be thoroughly tested in clinical studies. It also implies that this plant-based, non-synthetic, highly purified form of CBD and THC is produced following the FDA’s current Good Manufacturing Practices guidelines.

“MMJ International Holdings has pushed carefully for the past five years to formulate the capsule and log in all of the evidence required by the FDA for approval,” said Dr. Elio Mariani, MMJ’s CEO. The president of MMJ, Duane Boise, also added that among MMJ’s lead treatments are MMJ-001 and MMJ-002. Both capsules are based on a colloidal solution of highly purified extracts of THC, CBD, and other compounds from the cannabis plant.

MMJ-001 is being evaluated as a therapy for muscle stiffness (spasticity) in individuals with multiple sclerosis. MMJ-002 is an experimental therapy for Huntington’s-related chorea (a neurological disorder with the characteristic symptom of involuntary jerking movements). The US Food and Medication Administration has designated MMJ-002 as an orphan drug (FDA).

“MMJ’s clinical trials will provide data to the FDA on patient dose, safety, and efficacy to establish that cannabis can cure critical tremors, a neurological condition that results in involuntary shaking,” Duane Boise said. “We are confident that our MMJ oral gel cap medication, which contains the marijuana plant’s distinctive pharmacological qualities, will be authorized by the FDA as an effective and safe drug,” Tim Moynahan, board chairman, added.

MMJ recently received DEA approval to import cannabis-based goods into the United States, a process that requires the collaboration of various government agencies, including the FDA, Health Canada, and the United States Drug Enforcement Agency (DEA). In addition, the company recently received DEA clearance for a schedule 1 cannabis experimental lab and is seeking final DEA approval for their API Bulk Manufacturing Registration to produce cannabis plants.

“Our competent team was working within the DEA and FDA requirements to acquire all clearances,” Boise stated. “MMJ may now move forward with developing our cannabis-derived, natural extracts for our oral gel capsule medications in clinical studies in the United States.”

The Marijuana Research and Expansion Act

In related news, President Biden signed the Marijuana Research and Expansion Act into law. This will speed up researchers’ bids for DEA schedule 1 registration authorization to undertake these trials. After seven hard years of waiting, the MMJ group of firms can finish their mission of performing clinical studies on Huntington’s Disease and Multiple Sclerosis. MMJ has received FDA Orphan Designation for its Huntington’s disease clinical trials.

The measure explicitly authorizes the Drug Enforcement Administration (DEA) to adopt specific procedures to register;

  • Practitioners to conduct marijuana research and
  • Producers supply marijuana for the research.

The measure authorizes MMJ businesses to possess, manufacture, sell, or dispense cannabidiol (CBD) or marijuana (THC) for medical research purposes. The measure also states that the US attorney general will have 2 months to approve or request additional data from the cannabis research applicant. It also makes it easier for MMJ researchers to obtain more significant amounts of cannabis.

The company’s CEO, Dr. Elio Mariani, claimed, “In the instance of MMJ, the company is developing a soft gel pill to treat the symptoms of Huntington’s Disease and Multiple Sclerosis. Other researchers could potentially use the gel capsule composition in clinical trials “.

The DEA MOA has been issued, and MMJ is on pace to earn a vertically integrated Schedule 1 cannabis production and cultivation license. The firm is also nearing the completion of its state-of-the-art marijuana center of excellence in Rhode Island. The MOA specifies how the firm plans to conduct business with the DEA when a few minor changes are made following the DEA’s requirements and the final registration is approved.

“These permits fall under severe DEA monitoring and require stringent regulations of operation, all of which MMJ has met,” said Jorge Jimenez, MMJ’s head of regulatory compliance. This year, MMJ was granted a schedule 1 analytical lab license. MMJ has teamed with the University of Connecticut since Schedule 1 licenses are generally issued to cultivators linked with an academic institution for research and development.

“MMJ is committed to furthering its research and development through a method that is in accordance with the government’s aim to prioritize public health, support innovation, and promote customer trust,” commented Duane Boise.

MMJ International Holdings Milestones

MMJ International Holdings recently secured a DEA license to import its proprietary cannabis extracts into the United States for possible cures for Multiple Sclerosis and Huntington’s Disease. After a significant amount of effort, the team has reached vital milestones, which include:

  1. Identified unique cannabis strains for high levels of CBD and THC.
  2. All necessary testing on dried and raw plant “buds” was completed following the FDA Botanical Drug Development Guidance.
  3. Developed a unique extraction method to maximize the levels of both THC and CBD
  4. Analyzed every component present in the extracts for other plant extracts and endocannabinoids.
  5. Chemical and physical stability data for every extract have been established (THC and CBD)
  6. Received DEA approval to import extracts from non-US countries to the US.
  7. Contract with a pharmaceutical business to formulate soft gelatin capsules with a predetermined THC/CBD ratio for phase 2 and 3 clinical trials.
  8. MMJ BioPharma Cultivation has completed arrangements with a sovereign Native American Indian country for a DEA-approved “grow” of the marijuana plant for pharmaceutical, academic, and research companies.
  9. The FDA granted Orphan Drug Approval for their patented soft gelatin dose formulation having a set ratio of THC and CBD for the clinical research of Huntington’s Chorea.

Conclusion

MMJ acknowledges the public’s interest in cannabis-derived and cannabis substances. The MMJ team is working hard to fill information gaps about their products’ chemistry, quality, and safety. “We are committed to developing our cannabis cultivation, lab formulations, and clinical studies in accordance with our purpose of prioritizing public health, fostering innovation, and promoting customer trust,” Duane Boise stated.

Source: https://cannabis.net/blog/medical/new-thccbd-pill-for-ms-and-huntingtons-disease-may-be-first-to-benefit-from-bidens-new-marijuan

Business

EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices

Published

on

By

A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.

Investigation Under Digital Markets Act Gains Momentum

The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.

Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.

Industry Groups Demand Swift Action

Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.

Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.

In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.

Google Denies Allegations

Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.

However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.

Potential Billion-Euro Penalties

If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.

Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.

Wider Implications for Big Tech

The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.

A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.

As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.

Continue Reading

AI & Technology

Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations

Published

on

By

Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).

The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.

Trial Push Despite Multi-Million Euro Settlement

The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.

Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.

A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.

Allegations of VAT Evasion Through Marketplace Sellers

At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.

Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.

Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.

Italian Government Named as Affected Party

In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.

Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.

Multiple Investigations Add to Pressure

The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.

Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.

In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.

Amazon Denies Allegations

Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.

Broader Impact on Europe’s Digital Economy

If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.

With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.

Continue Reading

Aviation

IndiGo Crisis Exposes Risks of Monopoly: What If Telecom or E-commerce Collapses Next?

Published

on

By

Airports across India witnessed scenes of distress and confusion as thousands of passengers were stranded due to IndiGo’s massive flight disruptions. Families with medical emergencies, funerals, and personal crises were left helpless as the airline cancelled hundreds of flights without adequate communication or support.

Passengers described desperate situations — a mother pleading for sanitary pads for her daughter, a woman unable to transport her husband’s coffin, and others stranded while trying to reach family funerals or hospitals. “It was like a lockdown at the airport,” one passenger said, describing the panic that unfolded as IndiGo’s mismanagement crippled operations nationwide.

Root Cause: IndiGo’s Market Monopoly

The turmoil, industry experts argue, stems from IndiGo’s monopolistic control over India’s domestic aviation market. The airline operates nearly 2,100 flights daily and holds around 60% market share — meaning every second plane flying within India belongs to IndiGo.

This dominance has given the company unparalleled influence. When IndiGo falters, the entire aviation system suffers. Passengers are left with few alternatives, as other airlines lack capacity to absorb stranded travellers. The result: skyrocketing ticket prices, chaos at terminals, and total dependence on a single private operator.

Aviation pioneer Captain G.R. Gopinath, founder of Air Deccan, criticised the government’s inaction, noting that on some routes, IndiGo’s economy fares surged to ₹1 lakh. He compared the situation to a hostage crisis, writing that the airline “held the system ransom” and forced regulators to defer new safety rules meant to protect pilots and passengers.

Government Intervention and Regulatory Weakness

The crisis erupted after IndiGo failed to comply with the Flight Duty Time Limitations (FDTL) — rules introduced by the DGCA in January 2024 requiring adequate rest for pilots. Despite having nearly two years to adapt, IndiGo blamed the rule for operational disruptions, citing a shortage of pilots.

Under mounting public pressure, the government stepped in, temporarily relaxing FDTL norms and capping airfare hikes. Officials claimed the move was to protect passengers, but analysts say it exposed the state’s vulnerability to corporate monopolies. “The government had no option but to yield,” said one aviation policy expert, pointing out that ignoring safety regulations for short-term relief could have long-term consequences.

The crisis also rekindled memories of the June 2025 Air India crash near London, which claimed over 240 lives. Experts warn that compromising pilot rest and safety standards to maintain flight schedules could risk another tragedy.

If Telecom Giants Fail: A National Paralysis

The article raises a troubling question — what if a similar crisis struck the telecom sector, where Jio and Airtel together control nearly 80% of subscribers and serve over 780 million users?

If both networks failed simultaneously, the repercussions would be catastrophic. Internet shutdowns would halt UPI transactions, online banking, OTP verifications, video calls, OTT streaming, and emergency communications. Critical services such as airports, hospitals, stock exchanges, and small businesses — many of which rely on WhatsApp and digital payments — would come to a standstill.

In essence, a telecom breakdown could paralyse India’s digital economy, exposing the nation’s dependence on a duopoly.

E-commerce Monopoly: Another Fragile Ecosystem

The same risk looms over the e-commerce sector, where Amazon and Flipkart dominate nearly 80% of the market. A disruption similar to IndiGo’s could cripple daily life — halting delivery of groceries, medicines, and essential goods, freezing refunds and customer support, and leaving small sellers without platforms to trade.

Local retailers, freed from competition, might exploit shortages by inflating prices. Such a scenario underscores the perils of market centralisation in sectors critical to everyday living.

A Wake-Up Call for Regulators

The IndiGo crisis, analysts say, is a warning shot for policymakers and regulators. A single company’s operational failure exposed systemic weaknesses in India’s infrastructure and consumer protection mechanisms.

As the aviation regulator DGCA investigates and IndiGo works to restore normalcy, the broader lesson remains clear: unchecked monopoly power in any essential service — whether air travel, telecom, or e-commerce — poses a direct threat to economic stability and citizen welfare.

Without stronger competition laws, redundancy frameworks, and regulatory oversight, India risks repeating this crisis across multiple sectors — each time with millions of citizens paying the price.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News